Questran ( DrugBank: - )

---

4 diseases

ID	Disease name (Link within this page)	Number of trials
93	Primary biliary cholangitis	1
254	Porphyria	1
297	Alagille syndrome	1
338	Progressive familial intrahepatic cholestasis	1

93. Primary biliary cholangitis

---

Clinical trials : 298 /  Drugs : 252 - (DrugBank : 59) / Drug target genes : 35 - Drug target pathways : 115

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02963077 (ClinicalTrials.gov)	July 2013	1/11/2016	A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384	A Phase I, Double-Blind Single and Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of A4250 as Monotherapy, and in Combination With Colonic Release Cholestyramine (A3384) or Commercially Available Cholestyramine (Questran™) in Healthy Subjects	Orphan Cholestatic Liver Diseases;Primary Biliary Cirrhosis;Progressive Familial Intrahepatic Cholestasis;Alagille Syndrome	Drug: A4250;Drug: CRC (A3384);Drug: Questran;Drug: Placebo	Albireo	NULL	Completed	18 Years	60 Years	Both	94	Phase 1	NULL

254. Porphyria

---

Clinical trials : 72 /  Drugs : 53 - (DrugBank : 16) / Drug target genes : 19 - Drug target pathways : 35

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2007-002863-28-GB (EUCTR)	26/09/2007	15/08/2007	Investigation into the use of colestyramine as a therapy for patients with erythropoietic protoporphyria - EPP001	Investigation into the use of colestyramine as a therapy for patients with erythropoietic protoporphyria - EPP001	Erythropoietic protoporphyria (EPP) MedDRA version: 9.1;Level: LLT;Classification code 10015289;Term: Erythropoietic protoporphyria	Trade Name: Questran Product Name: Questran INN or Proposed INN: COLESTYRAMINE	Guy's & St Thomas' NHS Foundation Trust	NULL	Not Recruiting			Female: yes Male: yes	21	Phase 4	United Kingdom

297. Alagille syndrome

---

Clinical trials : 45 /  Drugs : 21 - (DrugBank : 10) / Drug target genes : 3 - Drug target pathways : 5

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02963077 (ClinicalTrials.gov)	July 2013	1/11/2016	A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384	A Phase I, Double-Blind Single and Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of A4250 as Monotherapy, and in Combination With Colonic Release Cholestyramine (A3384) or Commercially Available Cholestyramine (Questran™) in Healthy Subjects	Orphan Cholestatic Liver Diseases;Primary Biliary Cirrhosis;Progressive Familial Intrahepatic Cholestasis;Alagille Syndrome	Drug: A4250;Drug: CRC (A3384);Drug: Questran;Drug: Placebo	Albireo	NULL	Completed	18 Years	60 Years	Both	94	Phase 1	NULL

338. Progressive familial intrahepatic cholestasis

---

Clinical trials : 60 /  Drugs : 26 - (DrugBank : 6) / Drug target genes : 2 - Drug target pathways : 2

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02963077 (ClinicalTrials.gov)	July 2013	1/11/2016	A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384	A Phase I, Double-Blind Single and Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of A4250 as Monotherapy, and in Combination With Colonic Release Cholestyramine (A3384) or Commercially Available Cholestyramine (Questran™) in Healthy Subjects	Orphan Cholestatic Liver Diseases;Primary Biliary Cirrhosis;Progressive Familial Intrahepatic Cholestasis;Alagille Syndrome	Drug: A4250;Drug: CRC (A3384);Drug: Questran;Drug: Placebo	Albireo	NULL	Completed	18 Years	60 Years	Both	94	Phase 1	NULL